Insiders who reported open-market trades in the last 12 months at the companies Rick E. Winningham files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Bruce C. Cozadd - $27.78M in JAZZ purchases and sales in the last 12 months
Robert Iannone - $20.41M in JAZZ purchases and sales in the last 12 months
Neena M. Patil - $11.50M in JAZZ purchases and sales in the last 12 months
Eli Samaha - $5.91M in TBPH purchases and sales in the last 12 months
Patricia Carr - $1.66M in JAZZ purchases and sales in the last 12 months
Eran Broshy - $1.66M in TBPH purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Rick E. Winningham is a corporate insider, tracked as CHIEF EXECUTIVE OFFICER, Director of Theravance Biopharma, Inc. (TBPH). InsiderAlpha holds 17 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Rick E. Winningham submitted recently?
4 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Rick E. Winningham been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($1.66M) across all tracked filings.
Rick E. Winningham is CHIEF EXECUTIVE OFFICER, Director of Theravance Biopharma, Inc. (TBPH). 17 SEC Form 4 filings on record going back to 2024, most recently on 25 September 2026. Most recent open-market trade: sold $662K of JAZZ on 27 May 2026. Lifetime open-market sales: $1.66M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Rick E. Winningham.
InsiderAlpha's records for Rick E. Winningham go back to 2024: 17 primary Form 4 filings, an average of 5.7 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
